Clinical efficacy of camrelizumab-based combination therapy strategy in the treatment of advanced esophageal squamous cell carcinoma
Objective To investigate the clinical efficacy of camrelizumab-based combination therapy strategy in the treatment of advanced esophageal squamous cell carcinoma.Method A total of 48 patients with advanced/metastatic esophageal squamous cell carcinoma were divided into the control group(n=12)and the observation group(n=36)accord-ing to different treatment methods.The patients in the control group were treated with camrelizumab,and the patients in the observation group were treated with camrelizumab combined with chemotherapy or targeted therapy,including 29 cas-es of camrelizumab combined with chemotherapy and 7 cases of camrelizumab combined with apatinib.The clinical effi-cacy,incidence of survival and adverse reactions of the two groups were compared.Result The disease control rate(DCR)in the observation group was 72.22%(26/36),which was higher than 33.33%(4/12)in the control group,the dif-ference was statistically significant(P<0.05).The median progression-free survival(PFS)and overall survival(OS)of the observation group were longer than those of the control group,the differences were statistically significant(P<0.05).There were no significant differences in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Camrelizumab combined with chemotherapy or targeted therapy can improve the PFS and OS of patients with advanced esophageal squamous cell carcinoma,and it is well tolerated.
esophageal squamous cell carcinomaprogrammed cell death 1 inhibitorcamrelizumabefficacy
NETL
NSTL
万方数据
维普
